DNA repair mechanisms associated with cellular resistance to antitumor drugs: Potential novel targets

Anti-Cancer Drugs

Volumn 9, Issue 2, 1998, Pages 105-123

  Barret, Jean Marc ^a   Hill, Bridget T ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

Antitumor drug; Cellular resistance; DNA repair; Novel targets

Indexed keywords

6 O ALKYLGUANINE DNA ALKYLTRANSFERASE; ANTIBODY; ANTINEOPLASTIC AGENT;

BACTERIUM; CANCER CELL; DNA DAMAGE; DNA PROBE; DNA REPAIR; DRUG RESISTANCE; EXCISION REPAIR; MAMMAL CELL; PRIORITY JOURNAL; REVIEW; RNA PROBE; YEAST;

EID: 0031913158     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199802000-00001     Document Type: Review

References (184)

1. Lehnert M. Clinical multidrug resistance in cancer: a multifactorial problem. Eur J Cancer 1996; 32A: 912-20.
2. Hill BT. Drug resistance: an overview of the current state of the art. Int J Oncol 1996; 9: 197-203.
3. 6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res 1990; 50: 6119-29.
4. Calsou P, Salles B. Role of DNA repair in the mechanisms of cell resistance to alkylating agents and cisplatin. Cancer Chemother Pharmacol 1993; 32: 85-9.
5. Chaney SG, Sancar A. DNA repair enzymatic mechanisms and relevance to drug response. J Natl Cancer Inst 1996; 88: 1346-60.
6. Andrews PA, Jones JA, Varki NM, Howell SB. Rapid emergence of acquired cis-platinum(II) resistance in an in vivo model of human ovarian carcinoma. Cancer Commun 1990; 2: 93-100.
7. Sancar A. DNA repair in humans. Annu Rev Genet 1995; 29: 69-105.
8. Friedberg EC, Walker GC., Siede W, eds. DNA repair and mutagenesis. Washington, DC: ASM Press 1995.
9. Wood RD. DNA repair in eukaryotes. Annu Rev Biochem 1996; 65: 135-67.
10. 6-alkylguanine-DNA alkyltransferase. Prog Nucleic Acid Res 1995; 51: 170-223.
11. 6-benzylguanine and its role in chemotherapy. Clin Cancer Res 1997; 3: 837-47.
12. 6-alkylguanine-DNA-alkyltransferase: a target for the modulation of drug resistance. Hematol Oncol Clin N Am 1995; 9: 431-49.
13. 6-methylguanine-DNA methyltransferase (MGMT) on the cytotoxic and recombinogeenic activity of difference antineoplastic drugs. Int J Cancer 1996; 65: 506-12.
14. 6-alkylguanine. FASEB J 1992; 6: 2302-10.
15. 6-methylguanine. Cancer Res 1996; 56: 5615-9.
16. 6-methylguanine-DNA methyltransferase in human normal and tumor tissue from brain, lung, and ovary. Cancer Res 1991; 51: 4131-4.
17. 6-benzylguanine using a transgenic model. Cancer Res 1996; 56: 1880-5.
18. 6-methylguanine in DNA to inactivation by alkylating agent including chloroethylnitrosoureas. Cancer Res 1984; 44: 2467-74.
19. Tsuzuki T, Sakumi K, Shiraishi A, et al. Targeted disruption of the DNA repair methyltransferase gene renders mice hypersensitive to alkylating agent. Carcinogenesis 1996; 17: 1215-20.
20. Belanich M, Pastor M, Randall T, et al. Retrospective study of correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. Cancer Res 1996; 56: 783-8.
21. 6-methylguanine-DNA methyl-transferase associated with resistance to alkylating drugs in a mammalian cell line. J Biol Chem 1997; 272: 13250-4.
22. 6-methylguanine-DNA methyl-transferase in mammalian cells by DNA-damaging treatments. Mol Cell Biol 1991; 11: 4660-8.
23. 6-methylguanine-DNA methyltransferase mRNA in rat hepatoma cells. Biochim Biophys Acta 1992; 1171: 35-40.
24. 6-benzylguanine. Biochemistry 1993; 32: 11998-2006.
25. 6-benzylguanine analogues on sensitivity of human tumor cells to the cytotoxic effects of alkylating agents. Cancer Res 1991; 51: 3367-72.
26. 6-benxylguanine on the response to 1,3-bis(2-chloroethyl)-1-nitrosourea in the Dunning R3327G model of prostatic cancer. Cancer Chemother Pharmacol 1993; 32: 221-5.
27. 6-benzylguanine on the sensitivity of human tumor xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea and on DNA interstrand cross-link formation. Cancer Res 1992; 52: 1171-5.
28. Friedman HS, Dolan ME, Moschel RC, et al. Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiforme. J Natl Cancer Inst 1992; 84: 1926-31.
29. 6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) in a human colon cancer xenograft completely resistant to BCNU alone. Biochem Pharmacol 1993; 45: 483-91.
30. 6-benzylguanine enables the specific therapy of nitrosourea-resistant intracranial human glioma xenografts in athymic rats with 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Chemother Pharmacol 1997; 39: 307-16.
31. 6-methylguanine-DNA transferase in resistance of human brain tumor cell lines to the clinically relevant methylating agents temozolomide and streptozotocin. Clin Cancer Res 1996; 2: 735-41.
32. 6-alkylguanine alkyltransferase-directed DNA repair in metastatic colon cancers. J Clin Oncol 1995; 13: 2301-8.
33. 6-benzylguanine and its effectiveness against human brain tumor xenografts when given in polyethylene glycol or cremophor-EL. Cancer Chemother Pharmacol 1994; 35: 121-6.
34. 6-alkylguanine-DNA alkyltransferase and N,N′-bis(2-chloroethyl)-N-nitrosourea. Biochem Pharmacol 1995; 50: 1141-8.
35. 6-benzylguanine. Cancer Res 1994; 54: 6221-7.
36. 6-fluorobenzylguanines on chloroethylnitrosourea cytotoxicity in tumor cells. Life Sci 1996; 58: 303-8.
37. 6-benzylguanine derivatives. Biochem Pharmacol 1997; 53: 1559-64.
38. 6-benzylguanine plus 1,3-bis(2-chloroethyl)-1-nitrosourea. Proc Natl Acad Sci USA 1996; 93: 14088-93.
39. Dolan ME. Inhibition of DNA repair as a means of increasing the antitumor activity of DNA reactive agents. Adv Drug Deliv Rev 1997; 26: 105-18.
40. Lindahl T, Karran P, Wood RD. DNA excision repair pathways. Curr Opin Gen Dev 1997; 7: 158-69.
41. Kubota Y, Nash RA, Klungland A, et al. Reconstitution of DNA base excision-repair with purified human proteins: interaction between DNA polymerase β and XRCC1 protein. EMBO J 1996; 15: 6662-70.
42. Klungland A, Lindahl T. Second pathway for completion of human DNA base excision-repair: reconstitution with purified proteins and requirement for DNase IV (FEN1). EMBO J 1997; 16: 3341-8.
43. Krokan HE, Standal R, Slupphaug G. DNA glycosylases in the base excision repair of DNA. Biochem J 1997; 325: 1-16.
44. Demple B, Harrison L. Repair of oxidative damage to DNA: enzymology and biology. Annu Rev Biochem 1994; 63: 915-48.
45. Matsumoto Y, Kim K. Excision of deoxyribose phosphate residues by DNA polymerase β during DNA repair. Science 1995; 269: 699-702.
46. Nealon K, Nichol ID, Kenny MK. Characterization of the DNA polymerase requirement of human base excision repair. Nucleic Acids Res 1996; 24: 3763-70.
47. Sobol RW, Horton JK, Kühn R, et al. Requirement of mammalian DNA polymerase-β in base-excision repair. Nature 1996; 379: 183-6.
48. Bennett RAO, Wilson III DM, Wong D, Demple B. Interaction of human apurinic endonuclease and DNA polymerase β in the base excision repair pathway. Proc Natl Acad Sci USA 1997; 94: 7166-9.
49. Caldecott KW, Aoufouchi S, Johnson P, Shall S. XRCC1 polypeptide interacts with polymerase β and possibly poly(ADP-ribose) polymerase, and DNA ligase III is a novel molecular 'nick-sensor' in vitro. Nucleic Acids Res 1996; 24: 4387-94.
50. Prasad R, Singhal RK, Srivastava DK, et al. Specific interaction of DNA polymerase β and DNA ligase I in a multiprotein base excision repair complex from bovine testis. J Biol Chem 1996; 271: 16000-7.
51. Wood RD, Shivji MKK. Which DNA polymerases are used for DNA-repair in eukaryotes? Carcinogenesis 1997; 18: 605-10.
52. Matijasevic Z, Boosalis M, Mackay W, Samson L, Ludlum DB. Protection against chloroethylnitrosourea cytotoxicity by eukaryotic 3-methyladenine DNA glycosylase. Proc Natl Acad Sci USA 1993; 90: 11855-9.
53. 3-methyladenine-DNA-glycosylase in human cells exposed to DNA damaging agents. DNA Cell Biol 1993; 12: 233-41.
54. Ibeanu G, Hartenstein B, Dunn WC, et al. Overexpression of human DNA repair protein N-methylpurine-DNA glycosylase results in the increased removal of N-methylpurines in DNA without a concomitant increase in resistance to alleviating agents in Chinese hamster ovary cells. Carcinogenesis 1992; 13: 1989-95.
55. Engelward BP, Dreslin A, Christensen J, et al. Repair-deficient 3-methyladenine DNA glycosylase homozigous mutant mouse cells have increased sensitivity to alkylation-induced chromosome damage and cell killing. EMBO J 1996; 15: 945-52.
56. Fornace Jr. AJ, Zmudzka B, Hollander C, Wilson SH. Induction of β-polymerase mRNA by DNA-damaging agents in Chinese hamster ovary cells. Mol Cell Biol 1989; 9: 851-3.
57. Friedman HS, Dolan ME, Kaufmann SH, et al. Elevated DNA polymerase α, DNA polymerase β, and topoisomerase II in a melphalan-resistant rhabdomyosarcoma xenographt that is cross-resistant to nitrosoureas and topotecan. Cancer Res 1994; 54: 3487-93.
58. Gomi A, Shinoda S, Sakai R, et al. Elevated expression of DNA polymerase β gene in glioma cell lines with acquired resistance to 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethy)-3-nitrosourea. Biochem Biophys Res Commun 1996; 227: 558-63.
59. Moynihan K, Elion GB, Ali-Osman F, et al. Enhancement of melphalan activity by inhibition of DNA polymerase-α and DNA polymerase-β. Cancer Chemother Pharmacol 1996; 38: 349-54.
60. Ludlum DB. DNA alkylation by haloethylnitrosoureas: nature of modifications produced and their enzymatic repair of removal. Mutat Res 1990; 233: 117-26.
61. Singer B, Hang B. What structural features determine repair enzyme specificity and mechanism in chemically modified DNA? Chem Res Toxicol 1997; 10: 713-32.
62. Schärer OD, Verdine G. A designed inhibitor of base-excision DNA repair. J Am Chem Soc 1995; 117: 10781-2.
63. Bouayadi K, Hoffman J-S, Fons P, et al. Overexpression of DNA polymerase β sensitizes mammalian cells to 2′,3′-deoxycytidine and 3′-azido-3′-deoxythymidine. Cancer Res 1997; 57: 110-6.
64. Pelletier H, Sawaya MR, Wolfle W, Wilson SH, Kraut J. Crystal structures of human DNA polymerase β complexed with DNA: implication for catalytic mechanism, processivity, and fidelity. Biochemistry 1996; 35: 12742-61.
65. Barzilay G, Walker LJ, Rothwell DG, Hickson ID. Role of the HAP1 protein in repair of oxidativc DNA damage and regulation of transcription factors. Br J Cancer 1996; 74: S145-50.
66. Constant J-F, Fkeyrat A, Demeunynck M, et al. Design of molecules which specifically cleave abasic sites in DNA. Anti-Cancer Drugs Des 1990; 5: 59-62.
67. Belmont P, Boudali A, Constant J-F, et al. Efficient and versatile chemical tools for cleavage of abasic sites in DNA. New J Chem 1997; 21: 47-54.
68. Fkyerat A, Demeunynck M, Constant J-F, Michon P, Lhomme J. A new class of artificial nucleases that recognize and cleave a purinic site in DNA with great selectivity and efficiency. J Am Chem Soc 1993; 115: 9952-9.
69. Malvy C, Prévost P, Gansser C, Viel C, Paoletti C. Efficient breakage of DNA apurinic sites by indole-amine related 9-amino-ellipticine. Chem-Biol Interact 1986; 57: 41-53.
70. Vasseur JJ, B. R, Imbach JL, et al. Structure of the adduct formed between 3-amino-carbazole and the apurinic site oligonucleotide model [Tp(Ap)pT]. J Org Chem 1987; 52: 4994-8.
71. Behmoaras T, Toulme JJ, Hélène C. A tryptophan-containing peptide recognizes and cleaves DNA at apurinic sites. Nature 1981; 292: 858-9.
72. Grafström RH, Sun T, Doleniak D. AP endonuclease: a possible target for a novel tumoricidal compound. In: Freiberg E, Lindahl T, Walker G, organizers. Repair and processing of DNA damage. Taos, NM: 1995; 279.
73. Price A. The repair of ionising radiation-induced damage to DNA. Cancer Biol 1993; 4: 61-71.
74. Ruf A, Ménissier de Murcia J, de Murcia GM, Schulz GE. Structure of the catalytic fragment of poly(ADP-ribose) polymerase from chicken. Proc Natl Acad Sci USA 1996; 93: 7481-5.
75. Berger S, Sudar DC, Berger NA. Metabolic consequences of DNA damage: DNA damage induces alterations in glucose metabolism by activation of poly(ADP-ribose) polymerase. Biochem Biophys Res Commun 1986; 134: 227-32.
76. Boulikas T. Poly(ADP-ribosyl)ation, DNA strand breaks, chromatin and cancer. Toxicol Lett 1993; 67: 129-50.
77. Whitacre CM, Hashimoto H, Tsai M-L, et al. Involvment of NAD-poly-(ADP-ribose) metabolism in p5.3 regulation and its consequences. Cancer Res 1995; 55: 3697-701.
78. Rawling JM, Alvarez-Gonzalez R. TFIIF, a basal eukaryotic transcription factor, is a substrate for poly(ADP-ribosyl)ation. Biochem J 1997; 324: 249-53.
79. Marks DI, Fox RM. DNA damage, poly(ADP-rybosyl)ation and apoptotic cell death as a potential common pathway of cytotoxic drug action. Biochem Pharmacol 1991; 42: 1859-67.
80. Shah GM, Shah RG, Poirier GG. Different cleavage pattern for poly(ADP-ribose) polymerase during necrosis and apoptosis in HL-60 cells. Biochem Biophys Res Comm 1996; 229: 838-44.
81. Lindahl T, Satoh MS, Dianov G. Enzymes acting at strand interruptions in DNA. Phil Trans R Soc Lond 1995; 347: 57-62.
82. Waldman BC, Waldman AS. Illegitimate and homologous recombination in mammalian cells: differential sensitivity to an inhibitor of poly(ADP-ribosylation). Nucleic Acids Res 1990; 18: 5981-8.
83. Cleaver JE, Morgan WF. Poly(ADP-ribose)polymerase: a perplexing participant in cellular responses to DNA breakage Mutat Res 1991; 257: 1-18.
84. Wang Z-Q, Auer B, Stingl L, et al. Mice lacking ADPRT and poly(ADP-ribosyl)ation develop normally but are susceptible to skin disease. Gene Dev 1995; 9: 509-20.
85. Ménissier-de Murcia J, Niedergang C, Trucco C, et al. Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. Proc Natl Acad Sci USA 1997; 94: 7303-7.
86. Weinfeld M, Chaudhry MA, D'Amours D, et al. Interaction of DNA-dependent protein kinase and poly(ADP-ribose) polymerase with radiation-induced DNA strand breaks. Radiat Res 1997; 148: 22-8.
87. Lautier D, Lagueux J, Thibodeau J, Ménard L, Poirier G. Molecular and biochemical features of poly(ADP-ribose) metabolism. Mol Cell Biochem 1993; 122: 171-93.
88. Chatterjee S, Cheng MF, Berger NA. Hypersensitivity to clinicay useful alkylating agents and radiation in poly(ADP-ribose) polymerase-deficient cell lines. Cancer Commun 1990; 2: 401-7.
89. Chatterjee S, Cheng MF, Berger SJ, Berger NA. Alkylating agent hypersensitivity in poly(adenosine diphosphate-ribose) polymerase deficient cell lines. Cancer Commun 1991; 3: 71-5.
90. Bhatia K, Pommier Y, Giri C, et al. Expression of poly (ADP-ribose) polymerase gene following natural and induced DNA strand breakage and effect of hyperexpression on DNA repair. Carcinogenesis 1990; 11: 123-8.
91. Urade M, Sugi M, Mima T, Ogura T, Matsuya T. High induction of poly(ADP-ribose) polymerase activity in bleomycin-resistant HeLa cells. Jpn J Cancer Res 1989; 80: 464-8.
92. Chen G, Zeller WJ. Increased poly(ADP-ribose) formation in cisplatin-resistant rat ovarian tumor cells. Anticancer Res 1994; 14: 1462-8.
93. Bernges F, Bürkle A, Küpper J-H, Zeller WJ. Functional overexpression of human poly(ADP-ribose) polymerase in transfected rat tumor cells. Carcinogenesis 1997; 18: 663-8.
94. van Gool L, Meyer R, Tobiasch E, et al. Overexpression of human poly(ADP-ribose) polymerase in transfected hamster cells to increased poly(ADP-ribosyl)ation and cellular sensitization to γ irradiation. Eur J Biochem 1997; 244: 15-20.
95. Küpper J-H, Müller M, Bürkle A. Trans-dominant inhibition of poly(ADP-ribosyl)ation potentiates carcinogen-induced gene amplification in SV40-transformed Chinese hamster cells. Cancer Res 1996; 56: 2715-7.
96. August ME, Cooper DL, Prusoff WH. Inhibition of poly(adenosine diphosphate-ribose) polymerase by thymidine and thymidine analogues in L1210 cells and its relationship to the potentiation of the antitumor activity of 1,3-bis(2-chloroethyl)-1-nitrosourea but not of 3′-[3-(2-chloroethyl)-3-nitrosoureido]-3′-deoxythymidine. Cancer Res 1991; 51: 1586-90.
97. Banasik M, Komura H, Shimoyama M, Ueda K. Specific inhibitors of poly(ADP-ribose) synthetase and mono(ADP-ribosyl)transferase. J Biol Chem 1992; 267: 1569-75.
98. Horsman MR. Nicotinamide and other benzamide analogs as agents for overcoming hypoxic cell radiation resistance in tumors. Acta Oncol 1995; 34: 571-87.
99. Griffin RJ, Pemberton LC, Rhodes D, et al. Novel potent inhibitors of the DNA repair enzyme poly(ADP-ribose)-polymerase (PARP). Anti-Cancer Drug Des 1995; 10: 507-14.
100. Bellamacina CR. The nicotinamide dinucleotide binding motif: a comparison of nucleotide binding proteins. FASEB J 1996; 10: 1257-69.
101. Griffin RJ, Curtin NJ, Newell DR, et al. The role of inhibitors of poly(ADP-ribose) polymerase as resistance-modifying agents in cancer therapy. Biochimie 1995; 77: 408-22.
102. 6-alkylguanine DNA-alkyltransferase or poly(ADP-ribose) polymerase increases susceptibility of leukemic cells to apoptosis induced by temozolomide. Mol Pharmacol 1997; 52: 249-58.
103. Ding R, Pommier Y, Kang VH, Smulson M. Depletion of poly(ADP-ribose) polymerase by antisens RNA expression results in a delay in DNA strand break rejoining. J Biol Chem 1992; 267: 12804-12.
104. Olsson AR, Sheng Y, Pero RW, Chaplin DJ, Horsman MR. DNA damage and repair in tumor and non-tumor tissues of mice induced by nicotinamide. Br J Cancer 1996; 74: 368-73.
105. Sancar A. DNA excision repair. Annu Rev Biochem 1996; 65: 43-81.
106. Ma L, Hoeijmakers JHJ, van der Eb AJ. Mammalian nucleotide excision repair. Biochim Biophys Acta 1995; 1242: 137-64.
107. Collins AR. Mutant rodent cell lines sensitive to ultraviolet light, ionizing radiation and cross-linking agents: a comprehensive survey of genetic and bio chemical characteristics. Mutat Res 1993; 293: 99-118.
108. Wood RD. Protein that participate in nucleotide excision repair of DNA in mammalian cells. Phil Trans R Soc 1995; 347: 69-74.
109. Chu G. Cellular responses to cisplatin. The role of DNA-binding proteins and DNA repair. J Biol Chem 1994; 269: 787-90.
110. Friedberg EC. Relationships between DNA repair and transcription. Annu Rev Biochem 1996; 65: 15-42.
111. Larminat F, Bohr VA. Role of the human ERCC-1 gene in gene-specific repair of cisplatin-induced DNA damage. Nucleic Acids Res 1994; 22: 3005-10.
112. Sijbergs AM, van der Spek PJ, Odijk H, et al. Mutational analysis of the human nucleotide excision repair gene ERCC1. Nucleic Acids Res 1996; 24: 3370-80.
113. Calsou P, Barret J-M, Cros S, Salles B. DNA excision-repair synthesis is enhanced in a murine leukemia L1210 cell line resistant to cisplatin. Eur J Biochem 1993; 211: 403-9.
114. Zeng-Rong N, Paterson J, Alpert L, et al. Elevated DNA repair capacity is associated with intrinsic resistance of lung cancer chemotherapy. Cancer Res 1995; 55: 4760-4.
115. Yen L, Woo A, Christopoulopoulos G, et al. Enhanced host cell reactivation capacity and expression of DNA repair genes in human breast cancer cells resistant to bifunctional alkylating agents. Mutat Res 1995; 337: 179-89.
116. Dong Q, Bullock N, Ali-Osman F, et al. Repair analysis of 4-hydroperoxycyclophosphamide-induced DNA interstrand crosslinking in the c-myc gene in 4-hydroperoxycyclophosphamide-sensitive and -resistant medullo blastoma cell lines. Cancer Chemother Pharmacol 1996; 37: 242-6.
117. Dabholkar M, Vionnet J, Bostickbruton F, Yu JJ, Reed E. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 1994; 94: 703-8.
118. States JC, Reed E. Enhanced XPA mRNA levels in cisplatin-resistant human ovarian cancer are not associated with XPA mutations or gene amplification. Cancer Lett 1996; 108: 233-7.
119. Lee KB, Parker RJ, Bohr V, Cornelison T, Reed E. Cisplatin sensitivity/resistance in UV repair-deficient Chinese hamster ovary cells of complementation groups 1 and 3. Carcinogenesis 1993; 14: 2177-80.
120. Anderson BS, Sadeghi T, Siciliano MJ, Legerski R, Murray D. Nucleotide excision repair genes as determinants of cellular sensitivity to cyclophosphamide analogs. Cancer Chemother Pharmacol 1996; 38: 406-16.
121. Damia G, Imperatori L, Stefanini M, D'Incalci M. Sensitivity of CHO mutant cell lines with specific defects in nucleotides excision repair to different anti-cancer agents. Int J Cancer 1996; 66: 779-83.
122. Dabholkar M, Bostick-Bruton F, Weber C, et al. ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Res 1992; 84: 1512-7.
123. Frosina G, Rossi O. Effect of topoisomerase poisoning by antitumor drugs VM 26, fostriecin and camptothecin on DNA repair replication by mammalian cell extracts. Carcinogenesis 1992; 13: 1371-7.
124. Thielmann HW, Popanda O, Gersbach H, Gilberg F. Various inhibitors of topoisomerases diminish repair-specific DNA incision in UV-irradiated human fibroblasts. Carcinogenesis 1993; 14: 2341-51.
125. Barret J-M, Calsou P, Kragh Larsen A, Salles B. A cisplatin-resistant murine leukemia cell line exhibits increased topoisomerase II activity. Mol Pharmacol 1994; 46: 431-6.
126. Barret J-M, Salles B, Provot C, Hill B. Evaluation of DNA repair inhibition by antitumor or antibiotic drugs using a chemiluminescence microplate assay. Carcinogenesis 1997; in press.
127. Bachur NR, Yu F, Johnson R, et al. Helicase inhibition by anthracycline anticancer agents. Mol Pharmacol 1992; 41: 993-8.
128. Bachur NR, Johnson R, Yu F, et al. Antihelicase action of DNA-binding anticancer agents: relationship to guanosine-cytidine intercalator binding. Mol Pharmacol 1993; 44: 1064-9.
129. Adjei AA, Budihardjo II, Rowinsky EK, et al. Cytotoxicity synergy between pyrazoloacridine (NSC 366140) and cisplatin in vitro: inhibition of platinum-DNA adduct removal. Clin Cancer Res 1997; 3: 761-70.
130. Barret J-M, Calsou P, Laurent G, Salles B. DNA repair activity in protein extracts of fresh human malignant lymphoid cells. Mol Pharmacol 1996; 49: 766-71.
131. Boothman DA, Schlegel R, Pardee AB. Anticarcinogenic of DNA-repair modulators. Mutat Res 1988; 202: 393-411.
132. Damia G, Tagliabue G, Zucchetti M, et al. Activity of aphidicolin glycinate alone and in combination with cisplatin in a murine ovarian tumor resistant to cisplatin. Cancer Chemother Pharmacol 1992; 30: 459-64.
133. O'Dwyers PJ, Moyer JD, Suffhess M, et al. Antitumor activity and biochemical effects of aphidicolin glycinate (NSC 303812) alone and in combination with cisplatin in vivo. Cancer Res 1994; 54: 724-9.
134. Bramson J, Panasci L. Potentiation of chlorambucil toxicity in B-CLL lymphocytes using the DNA synthesis inhibitors aphidicolin and 1-β-D-arabinofuranosylcytosine. Biochem Pharmacol 1995; 50: 131-5.
135. Sargent JM, Elgie AW, Williamson CJ, Taylor CG. Aphidicolin markedly increases the platinum sensitivity of cells from primary ovarian tumors. Br J Cancer 1996; 74: 1730-3.
136. Frankfurt OS, Seckinger D, Sugarbaker EV. Inhibition of DNA repair in cells treated with a combination of alkylating agents. Anticancer Res 1993; 13: 947-52.
137. Bergman AM, Ruiz van Haperen VWT, Veerman G. Synergistic interaction between gemcitabine and cisplatin in vitro. Clin Cancer Res 1996; 2: 521-30.
138. Peters GJ, Ruiz van Haperen VWT, Bergman AM, et al. Preclinical combination therapy with gemcitabine and mechanisms of resistance. Semin Oncol 1996; 23: 16-24.
139. Sandoval A, Consoli U, Plunkett W. Fludarabine-mediated inhibition of nucleotide excision repair induces apoptosis in quiescent human lyphocytes. Clin Cancer Res 1996; 2: 1731-41.
140. Iwasaki H, Huang P, Keating MJ, Plunkett W. Differential incorporation of ara-C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells. Blood 1997; 90: 270-8.
141. Crinò L, Scagliotti G, Marangolo M, et al. Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 1997; 15: 297-303.
142. Salles B, Frit P, Provot C, Jaeg J-P, Calsou P. In vitro eukaryotic DNA excision repair assays: An overview. Biochimie 1995; 77: 796-802.
143. Shinohara A, Ogawa T. Homologous recombination and the roles of double-strand breaks. Trends Biochem Sci 1995; 20: 387-91.
144. Zdzienicka MZ. Mammalian mutants defective in the response to ionizing radiation-induced DNA damage. Mutat Res DNA Repair 1995; 336: 203-13
145. Jeggo PA. DNP-PK: at the cross-roads of biochemistry and genetics. Mutat Res 1997; 384: 1-14.
146. Lees-Miller SP. The DNA-dependent protein kinase, DNA-PK: 10 years and no ends in sight. Biochem Cell Biol 1996; 74: 503-12.
147. Pang D, Yoo S, Dynan S, Jung M, Dritschilo A. Ku proteins join DNA fragments as shown by atomic force microscopy. Cancer Res 1997; 57: 1412-5.
148. Tuteja N, Tuteja R, Ochem A, et al. Human DNA helicase II: novel DNA unwinding enzyme identified as the Ku autoantigen. EMBO J 1994; 13: 4991-5001.
149. Jeggo PA, Taccioli GE, Jackson SP. Menage a trois: double strand break repair, V(D)J recombination and DNA-PK. BioEssays 1995; 17: 949-957.
150. Jackson SP, Jeggo PA. DNA double-strand break repair and V(D)J recombination. Involvement of DNA-PK. Trends Biochem Sci 1995, 20: 412-5.
151. Lieber MR, Grawunder U, Wu X, Yaneva M. Tying loose ends: roles of Ku and DNA-dependent protein kinase in the repair of double-strand breaks. Curr Opin Gen Dev 1997; 7: 99-104.
152. Critchlow SE, Bowater RP, Jackson SP. Mammalian DNA double-strand break repair protein XRCC4 interacts with DNA ligase IV. Curr Biol 1997; 7: 588-98.
153. Myung K, He DM, Eun SE, Hendrickson EA. KARP-1: a novel leucine zipper protein expressed from the Ku86 autoantigen locus is implicated in the control of DNA-dependent protein kinase activity. EMBO J 1997; 16: 3172-84.
154. Finnie NJ, Gottlieb TM, Blunt T, Jeggo PA, Jackson SP. DNA-dependent protein kinase defects are linked to deficiencies in DNA repair and V(D)J recombination. Phil Trans R Soc 1996; 351: 173-9.
155. Allalunis-Turner MJ, Lintott LG, Barron GM, Day III RS, Lees-Miller SP. Lack of correlation between DNA-dependent protein kinase activity and tumor cell radiosensitivity. Cancer Res 1995; 55: 5200-2.
156. Maity A, Kao G, Muschel RJ, McKenna WG. Potential molecular targets for manipuling the radiation response. Int J Radiat Oncol Biol Phys 1997; 37: 639-53.
157. Swaffar DS, Ireland CM, Barrows LR. A rapid mechanism-based screen to detect potential anti-cancer agents. Anti-Cancer Drugs 1994; 5: 15-23.
158. Waters RL, Lyons BW, Li TM, Chen DJ. Topoisomerase II activity in a DNA double-strand break repair deficient Chinese hamster ovary cell line. Mutat Res 1991; 254: 167-74.
159. Schwartz JL, Brinkman WJ, Kasten L, et al. Altered metaphase chromosome structure in xrs-5 cells is not related to its radiation sensitivity or defective DNA break rejoining. Mutat Res Fundam Mol Mech Mutagen 1995; 328: 119-26.
160. He DM, Lee SE, Hendrickson EA. Restoration of X-ray and etoposide resistance, Ku-end binding activity and V(D)J recombination to the Chinese hamster sxi-3 mutant by a hamster Ku86 cDNA. Mutat Res 1996; 363: 43-56.
161. Tuteja N, Phan TN, Tuteja R, Ochem A, Falaschi A. Inhibition of DNA unwinding and ATPase activities of human DNA helicase II by chemotherapeutic agents. Biochem Biophys Res Comm 1997; 236: 636-40.
162. Powis G, Bonjouklian R, Berggren MM, et al. Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase. Cancer Res 1994; 54: 2419-23.
163. Hartley KO, Gell D, Smith GCM, et al. DNA-dependent protein kinase catalytic subunit: a relative of phosphatidylinositol 3-kinase and the ataxia telangiectasia gene product. Cell 1995; 82: 849-56.
164. Price BD, Youmell MB. The phophatidylinositol 3-kinase inhibitor wortmannin sensitizes murine fibroblasts and human tumor cells to radiation and blocks induction of p53 following DNA damage. Cancer Res 1996; 56: 246-50.
165. Boulton S, Kyle S, Yalçintepe L, Durkacz BW. Wortmannin is a potent inhibitor of DNA double strand break but not single break repair in Chinese hamster ovary cells. Carcinogenesis 1996; 17: 2285-90.
166. 2-M delay. Clin Cancer Res 1997; 3: 1149-56.
167. Take Y, Kumano M, Hamano Y, et al. OK-1035, a selective inhibitor of DNA-dependent protein kinase. Biochem Biophys Res Commun 1995; 215: 41-7.
168. Take Y, Kumano M, Teraoka H, Nishimura S, Okuyama A. DNA-dependent protein kinase inhibitor (OK-1035) suppresses p21 expression in HCT116 cells containing wild-type p53 induced by adriamycin. Biochem Biophys Res Commun 1996; 221: 207-12.
169. Modrich P, Lahue R. Mismatch repair in replication fidelity, genetic recombination and cancer biology. Annu Rev Biochem 1996; 65: 101-33.
170. Kolodner R. Biochemistry and genetics of eukaryotic mismatch repair. Genes Dev 1996; 10: 1433-42.
171. Prolla TA, Abuin A, Bradley A. DNA mismatch repair deficient mice in cancer research. Semin Cancer Biol 1996; 7: 241-7.
172. Longley MJ, Pierce AJ, Modrich P. DNA polymerase δ is required for human mismatch repair in vitro. J Biol Chem 1997; 272: 10917-21.
173. Rhyu MS. Molecular mechanisms underlying hereditary nonpolyposis colorectal carcinoma. J Natl Cancer Inst 1996; 88: 240-51.
174. Kolodner RD. Mismatch repair mechanisms and relationship to cancer susceptibility. Trends Biochem Sci 1996; 20: 397-401.
175. Drummond JT, Anthoney A, Brown R, Modrich P. Cisplatin and adryamycin resistance are associated with Mutlα and mismatch repair deficiency in an ovarian tumor cell line. J Biol Chem 1996; 271: 19645-8.
176. Swann PF, Waters TR, Moulton DC, et al. Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. Science 1996; 273: 1109-11.
177. Aebi S, Kurdi-Haidar B, Gordon R, et al. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 1996; 56: 3087-90.
178. Fink D, Nebel S, Aebi S, et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Res 1996; 56: 4881-6.
179. Brown R, Hirst GL, Gallagher WM, et al. hMLH1 expression and cellular responses of ovarian tumor cells to treatment with cytotoxic anticancer agents. Oncogene 1997; 15: 45-52.
180. Karran P, Bignami M. DNA damage tolerance, mismatch repair and genome instability. BioEssays 1994; 16: 833-9.
181. Liu L, Markowitz S, Gereon SL. Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)-nitrosourea. Cancer Res 1996; 56: 5375-9.
182. Calsou P, Muller C, Frit P, Salles B. Ku protein complex is involved in nucleotide excision repair of DNA. C R Acad Sci 1996; 319: 179-82.
183. Kaufmann WK. Pathways of human cell post-replication repair. Carcinogenesis 1989; 10: 1-11.
184. Pinzani V, Bressolle F, Haug IJ, et al. Cisplatin-induced renal toxicity and toxicity-modulating strategies: a review. Cancer Chemother Pharmacol 1994; 35: 1-9.